AAAAAA

   
Results: 1-3 |
Results: 3
Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects
Authors: Creagh, T Ruckle, JL Tolbert, DT Giltner, J Eiznhamer, DA Dutta, B Flavin, MT Xu, ZQ
Citation: T. Creagh et al., Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects, ANTIM AG CH, 45(5), 2001, pp. 1379-1386
Pharmacokinetics of repaglinide in subjects with renal impairment
Authors: Marbury, TC Ruckle, JL Hatorp, V Andersen, MP Nielsen, KK Huang, WC Strange, P
Citation: Tc. Marbury et al., Pharmacokinetics of repaglinide in subjects with renal impairment, CLIN PHARM, 67(1), 2000, pp. 7-15
A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults
Authors: Dixon, R Engleman, K Kemp, J Ruckle, JL
Citation: R. Dixon et al., A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults, J CH AD PSY, 9(1), 1999, pp. 35-42
Risultati: 1-3 |